title: Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.
abstract: OBJECTIVE
  Neutralizing antibodies (NAbs) appearing during treatment with Interferon-beta (IFN-beta) reduce or abolish bioactivity and therapeutic efficacy. Initial combination therapy with methylprednisolone (MP) may reduce the frequency of NAb positive patients. We hypothesized that MP treatment might also reduce NAb levels and re-establish IFN-beta bioactivity in patients already NAb+, who discontinue IFN-beta therapy.
  
  
  METHODS
  In a 6-month open-label trial, we compared monthly high-dose pulsed MP treatment in 38 Nab positive patients with 35 NAb+, MP-untreated control patients discontinuing any therapy or switching to glatiramer acetate. All patients were NAb+ with an absent in vivo response to IFN-beta. NAbs were measured using a cytopathic effect assay and expressed as neutralizing capacity (NC) in percentage of added IFN-beta. Bioactivity was expressed as in vivo Myxovirus Resistance Protein A (MxA) mRNA induction in whole blood using real time PCR.
  
  
  RESULTS
  At the end of study, median NAb NC was 92% in both groups. Eight patients (21%) in the MP group and four patients (11%) in the control group had regained an in vivo MxA response to IFN-beta (P = 0.35).
  
  
  CONCLUSIONS
  Monthly pulsed MP treatment in NAb positive patients has no beneficial effect on NAb status or IFN-beta bioactivity.
authors.affiliation: Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Denmark. dan.hesse@rh.regionh.dk
authors.forename: D
authors.initials: D
authors.lastname: Hesse
authors.forename: J L
authors.initials: JL
authors.lastname: Frederiksen
authors.forename: N
authors.initials: N
authors.lastname: Koch-Henriksen
authors.forename: K
authors.initials: K
authors.lastname: Schreiber
authors.forename: E
authors.initials: E
authors.lastname: Stenager
authors.forename: A
authors.initials: A
authors.lastname: Heltberg
authors.forename: M
authors.initials: M
authors.lastname: Ravnborg
authors.forename: K
authors.initials: K
authors.lastname: Bendtzen
authors.forename: F
authors.initials: F
authors.lastname: Sellebjerg
authors.forename: P S
authors.initials: PS
authors.lastname: Sorensen
mesh_terms: D000328:Adult; D057134:Antibodies, Neutralizing / Q000096:biosynthesis* / Q000097:blood / Q000502:physiology; D002986:Clinical Trials as Topic / Q000379:methods; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D057134:Antibodies, Neutralizing; D018696:Neuroprotective Agents; D016899:Interferon-beta; D008775:Methylprednisolone